IS2135B - Lyfjablanda sem inniheldur solmítriptan - Google Patents

Lyfjablanda sem inniheldur solmítriptan

Info

Publication number
IS2135B
IS2135B IS6394A IS6394A IS2135B IS 2135 B IS2135 B IS 2135B IS 6394 A IS6394 A IS 6394A IS 6394 A IS6394 A IS 6394A IS 2135 B IS2135 B IS 2135B
Authority
IS
Iceland
Prior art keywords
solmitriptan
product containing
medicinal product
formulation
zolmitriptan
Prior art date
Application number
IS6394A
Other languages
English (en)
Icelandic (is)
Other versions
IS6394A (is
Inventor
Dearn Adam Roy
Williamson Sarah Louise
Summers Simon John
Coomber Trevor John
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10865629&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS2135(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IS6394A publication Critical patent/IS6394A/is
Publication of IS2135B publication Critical patent/IS2135B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IS6394A 1999-12-03 2002-05-24 Lyfjablanda sem inniheldur solmítriptan IS2135B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9928578.5A GB9928578D0 (en) 1999-12-03 1999-12-03 Pharmaceutical formulations
PCT/GB2000/004528 WO2001039772A1 (en) 1999-12-03 2000-11-28 Pharmaceutical formulations containing zolmitriptan

Publications (2)

Publication Number Publication Date
IS6394A IS6394A (is) 2002-05-24
IS2135B true IS2135B (is) 2006-08-15

Family

ID=10865629

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6394A IS2135B (is) 1999-12-03 2002-05-24 Lyfjablanda sem inniheldur solmítriptan

Country Status (28)

Country Link
US (2) US6750237B1 (es)
EP (1) EP1237551B1 (es)
JP (1) JP2003515559A (es)
KR (1) KR100670092B1 (es)
CN (1) CN1222287C (es)
AT (1) ATE291914T1 (es)
AU (1) AU778092B2 (es)
BR (1) BRPI0016138B8 (es)
CA (1) CA2392050C (es)
CZ (1) CZ301528B6 (es)
DE (1) DE60019162T2 (es)
EE (1) EE05305B1 (es)
ES (1) ES2236001T3 (es)
GB (2) GB9928578D0 (es)
HK (3) HK1048442B (es)
HU (1) HU229458B1 (es)
IL (2) IL149578A0 (es)
IS (1) IS2135B (es)
MX (1) MXPA02005319A (es)
NO (1) NO322119B1 (es)
NZ (1) NZ518862A (es)
PL (1) PL200679B1 (es)
PT (1) PT1237551E (es)
RU (1) RU2255736C2 (es)
SK (1) SK287228B6 (es)
UA (1) UA75059C2 (es)
WO (1) WO2001039772A1 (es)
ZA (1) ZA200203704B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8465468B1 (en) 2000-06-29 2013-06-18 Becton, Dickinson And Company Intradermal delivery of substances
GB9928578D0 (en) * 1999-12-03 2000-02-02 Zeneca Ltd Pharmaceutical formulations
SE0102855D0 (sv) * 2001-08-27 2001-08-27 Astrazeneca Ab Method of treatment
US20050256182A1 (en) * 2004-05-11 2005-11-17 Sutter Diane E Formulations of anti-pain agents and methods of using the same
US8216610B2 (en) 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
AU2005247048B2 (en) * 2004-05-28 2007-12-13 Imaginot Pty Ltd Oral therapeutic compound delivery system
US20060211751A1 (en) * 2004-11-19 2006-09-21 Reuven Izsak Zolmitriptan crystal forms
CN100341504C (zh) * 2004-12-01 2007-10-10 鲁南制药集团股份有限公司 佐米曲普坦速释制剂
EP3263117A1 (en) * 2005-11-28 2018-01-03 Imaginot Pty Ltd. Oral therapeutic compound delivery system
US20100048609A1 (en) * 2006-08-01 2010-02-25 Jacobs Jeffrey W Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
EP2081893B1 (en) * 2006-10-19 2011-03-23 Auspex Pharmaceuticals, Inc. Substituted indoles
KR101517415B1 (ko) 2008-05-14 2015-05-07 에스케이바이오팜 주식회사 난용성 항경련제를 함유하는 경비 항경련성 약학 조성물
JP5907975B2 (ja) 2010-10-15 2016-04-26 コンテラ ファーマ アンパルトセルスカブＣｏｎｔｅｒａ Ｐｈａｒｍａ Ａｐｓ 運動障害の治療のためのセロトニン受容体アゴニストの組み合わせ
JP6121734B2 (ja) * 2012-02-09 2017-04-26 久光製薬株式会社 マイクロニードル用ゾルミトリプタン含有コーティング組成物及びマイクロニードルデバイス
SG11201406690SA (en) 2012-04-18 2014-11-27 Contera Pharma Aps Orally available pharmaceutical formulation suitable for improved management of movement disorders
US11554229B2 (en) 2013-03-26 2023-01-17 OptiNose Inc. Nasal administration
KR101624049B1 (ko) 2014-10-29 2016-05-24 연세대학교 산학협력단 사카린을 이용한 용해도를 증가시킨 약제학적 조성물
EP3310360B1 (en) * 2015-06-19 2024-03-27 Beijing Artivila BioPharma Co. Ltd. Chiral specific boron-containing compounds and their use in treating cancer or amyloidosis
WO2017122161A1 (en) 2016-01-15 2017-07-20 Cadila Healthcare Limited An intranasal composition comprising 5ht1b/1d receptor agonists
EP3481385A1 (en) 2016-07-11 2019-05-15 Contera Pharma APS Pulsatile drug delivery system for treating morning akinesia
WO2019126766A1 (en) * 2017-12-21 2019-06-27 Taiwan Liposome Co., Ltd. Sustained-release triptan compositions and method of use the same through subdermal route or the like
US20210322343A1 (en) 2020-04-15 2021-10-21 Farzana Shaheen Nasally administered pharmaceutical composition for the treatment of epilepsy and related disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI9111010B (sl) * 1990-06-07 2005-02-28 Astrazeneca Ab 3,5-disubstituirani indolni derivati kot "5-HT1-podobni" receptorski agonisti
CN1230123A (zh) * 1996-07-11 1999-09-29 荷兰发马克有限公司 含碱性药物的酸加成盐的药物组合物
GB2315673A (en) 1996-08-01 1998-02-11 Merck & Co Inc Treatment of migraine
DE59804534D1 (de) * 1997-02-05 2002-07-25 Jago Res Ag Muttenz Medizinische aerosolformulierungen
GB9928578D0 (en) * 1999-12-03 2000-02-02 Zeneca Ltd Pharmaceutical formulations

Also Published As

Publication number Publication date
CZ301528B6 (cs) 2010-04-07
HUP0203597A3 (en) 2005-07-28
MXPA02005319A (es) 2002-12-06
CZ20021901A3 (cs) 2002-11-13
US6750237B1 (en) 2004-06-15
DE60019162D1 (de) 2005-05-04
IL149578A0 (en) 2002-11-10
CN1222287C (zh) 2005-10-12
UA75059C2 (uk) 2006-03-15
IS6394A (is) 2002-05-24
NO20022525L (no) 2002-05-28
BR0016138B1 (pt) 2013-09-10
HK1048445B (zh) 2005-08-26
PL200679B1 (pl) 2009-01-30
JP2003515559A (ja) 2003-05-07
AU778092B2 (en) 2004-11-18
PL357597A1 (en) 2004-07-26
DE60019162T2 (de) 2006-02-02
SK7532002A3 (en) 2002-12-03
BR0016138A (pt) 2002-08-06
CN1402636A (zh) 2003-03-12
AU1715701A (en) 2001-06-12
EE200200283A (et) 2003-06-16
US20040214899A1 (en) 2004-10-28
HUP0203597A2 (hu) 2003-02-28
IL149578A (en) 2008-04-13
NO20022525D0 (no) 2002-05-28
EP1237551A1 (en) 2002-09-11
GB2373726A (en) 2002-10-02
CA2392050A1 (en) 2001-06-07
HU229458B1 (en) 2013-12-30
RU2002117649A (ru) 2004-01-27
NO322119B1 (no) 2006-08-14
NZ518862A (en) 2004-02-27
GB9928578D0 (en) 2000-02-02
WO2001039772A1 (en) 2001-06-07
KR100670092B1 (ko) 2007-01-17
BRPI0016138B8 (pt) 2021-05-25
ES2236001T3 (es) 2005-07-16
PT1237551E (pt) 2005-07-29
GB2373726B (en) 2004-10-20
SK287228B6 (sk) 2010-03-08
US7220767B2 (en) 2007-05-22
EP1237551B1 (en) 2005-03-30
EE05305B1 (et) 2010-06-15
HK1048442B (zh) 2005-05-13
HK1053430A1 (en) 2003-10-24
ZA200203704B (en) 2003-10-29
HK1048442A1 (en) 2003-04-04
GB0214845D0 (en) 2002-08-07
CA2392050C (en) 2009-11-24
ATE291914T1 (de) 2005-04-15
HK1048445A1 (en) 2003-04-04
KR20020058051A (ko) 2002-07-12
RU2255736C2 (ru) 2005-07-10

Similar Documents

Publication Publication Date Title
IS6394A (is) Lyfjablanda sem inniheldur solmítriptan
GB0005251D0 (en) Therapeutic compounds
YU37602A (sh) Derivat pirolidinacetamida sam ili u kombinaciji za tretman poremećaja cns
AU2003297260A1 (en) Fast-disintegrating solid dosage forms being not friable and comprising pullulan
IL144294A0 (en) P53 inhibitors and therapeutic use of the same
AU4086101A (en) Sulphonamido-substituted bridged bicycloalkyl derivatives
GB0031088D0 (en) Medicaments
IS4972A (is) Notkun klóbindiefnisins klíókínól við að framleiða lyfjablöndu til að meðhöndla Alzheimers-sjúkdóm
HUP9901360A2 (hu) Cimicifuga racemosa-ból származó extraktum alkalmazása
DE60102590D1 (de) Darreichungsformen zur behandlung von oralen mykosen
ATE360428T1 (de) Analgetisches arzneimittel
IL115589A0 (en) Use of cck-b antagonists in pharmaceutical compositions
ATE319473T1 (de) Melagatran zur behandlung von entzündungen
SE0001916D0 (sv) Novel formulation
PL348202A1 (en) Pharmaceutically active composition and dispensing device
BG105984A (bg) Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението
MY141008A (en) Oral formulations of deoxypeganine and their uses
ATE334675T1 (de) Arzneimittel enthaltend substituierte 2,5- diaminomethyl-1h-pyrrole
UA38889A (uk) Лікувальний засіб "ліварекс" на основі диметоксіуреїдофосфорної кислоти
MY120631A (en) Novel pharmaceutical combination having analgesic activity